重组人促红素联合左卡尼汀治疗慢性肾衰竭血液透析患者的疗效

doi:10.3760/cma.j.issn.1007-1245.2023.18.019

摘要/Abstract

摘要：

目的　探讨重组人促红素联合左卡尼汀治疗慢性肾衰竭血液透析患者的疗效。方法　前瞻性选取2019年12月至2021年12月安阳市第三人民医院收治的94例慢性肾衰竭血液透析患者为研究对象，随机数字表法分为试验组和对照组，各47例。试验组男27例、女20例，年龄37～76（49.12±9.26）岁，透析病程5个月～5年，采用重组人促红素联合左卡尼汀治疗；对照组男26例、女21例，年龄39～79（51.32±10.14）岁，透析病程3个月～6年，采用重组人促红素治疗。两组均进行2个疗程，随访3个月，对比两组患者临床疗效，以及白蛋白、血红蛋白水平，并统计两组药物不良反应发生情况。统计学方法采用t检验、χ²检验。结果　与对照组相比，试验组总有效率较高［95.74%（45/47）比80.85%（38/47）］，差异有统计学意义（χ²=5.045，P<0.05）。治疗后，两组患者血红蛋白、白蛋白水平均较治疗前升高，且试验组均高于对照组［（114.15±16.04）g/L比（103.62±10.99）g/L、（39.93±5.79）g/L比（31.56±4.54）g/L］，差异均有统计学意义（t=3.713、7.799，均P<0.05）。试验组不良反应发生率低于对照组［6.38%（3/47）比21.28%（10/47）］，差异有统计学意义（χ²=4.374，P<0.05）。结论　通过对慢性肾衰竭血液透析患者采取重组人促红素联合左卡尼丁治疗可以进一步提高患者治疗效果，有利于更好地改善患者自身的白蛋白及血红蛋白水平，降低患者的不良反应发生率，值得在临床同类血液透析患者中进行推广和应用。

关键词:

慢性肾衰竭, 血液透析, 左卡尼汀, 重组人促红素, 白蛋白

Abstract:

Objective　To investigate the effect of recombinant human erythropoietin combined with L-carnitine for patients with chronic renal failure taking hemodialysis. Methods　A total of 94 patients with chronic renal failure who received hemodialysis in Anyang Third People's Hospital from December 2019 to December 2021 were selected as the research objects. They were divided into an experimental group and a control group by the random number table method, with 47 cases in each group. There were 27 males and 20 females in the experimental group; they were 37-76 (49.12±9.26) years old; they had been taking hemodialysis for 5 months to 5 years. There were 26 males and 21 females in the control group; they were 39-79 (49.12±9.26) years old; they had been taking hemodialysis for 3 months to 6 years. The experimental group took recombinant human erythropoietin and L-carnitine, and the control group recombinant human erythropoietin. Both groups were followed up for 3 months. The clinical efficacies, levels of albumin and hemoglobin, and incidences of adverse reactions were compared between the 2 groups. t and χ² tests were applied. Results　The total effective rate of the experimental group was higher than that of the control group [95.74% (45/47) vs. 80.85% (38/47)], with a statistical difference (χ²=5.045, P<0.05). After the treatment, the levels of albumin and hemoglobin in the two groups were significantly higher than those before the treatment, and the levels in the experimental group were higher than those in the control group [(114.15±16.04) g/L vs. (103.62±10.99) g/L and (39.93±5.79) g/L vs. (31.56±4.54) g/L], with statistical differences (t=3.713 and 7.799; both P<0.05). The incidence of adverse reactions in the experimental group was lower than that in the control group [6.38% (3/47) vs. 21.28% (10/47)], with a statistical difference (χ²=4.374, P<0.05). Conclusion　Recombinant human erythropoietin combined with levocanidine for patients with chronic renal failure taking hemodialysis can improve the effect and their levels of albumin and hemoglobin, and reduce the incidence of adverse reactions, so it is worth being clinically generalized in similar patients taking hemodialysis.

Key words:

Chronic renal failure, Hemodialysis, L-carnitine, Recombinant human erythropoietin, Albumin

王颖付冬梅李飒.

重组人促红素联合左卡尼汀治疗慢性肾衰竭血液透析患者的疗效 [J]. 国际医药卫生导报, 2023, 29(18): 2596-2600.

Wang Ying, Fu Dongmei, Li Sa.

Effect of recombinant human erythropoietin combined with L-carnitine for patients with chronic renal failure taking hemodialysis [J]. International Medicine and Health Guidance News, 2023, 29(18): 2596-2600.

参考文献

[1] 张曦,吴婷婷.1例血液透析患者抗菌药物治疗方案分析[J].国际医药卫生导报,2021,27(23):3648-3650.DOI:10.3760/cma.j.issn.1007-1245.2021.23.012.
[2] Kono K,Fujii H,Watanabe K,et al.Relationship between parathyroid hormone and renin-angiotensin-aldosterone system in hemodialysis patients with secondary hyperparathyroidism[J].J Bone Miner Metab,2021,39(2):230-236.DOI:10.1007/s00774-020-01139-5.
[3] Coyne DW,Goldberg S,Faber M,et al.A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD[J].Clin J Am Soc Nephrol,2014,9(9):1620-1626.DOI:10.2215/CJN.10661013.
[4] Sun Y,Tian B,Sheng Z,et al.Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis[J].BMC Nephrol,2020,21(1):316.DOI:10.1186/s12882-019-1639-9.
[5] Koc H,Hoser H,Akdag Y,et al.Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study[J].Int Urol Nephrol,2019,51(7):1261-1270.DOI:10.1007/s11255-019-02175-5.
[6] Kalantar-Zadeh K,Hollenbeak CS,Arguello R,et al.The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD[J].J Med Econ,2020,23(3):308-315.DOI:10.1080/13696998.2019. 1693385.
[7] Pouillès JM,Gosset A,Trémollieres F.Ménopause, traitement hormonal de ménopause et ostéoporose. RPC Les femmes ménopausées du CNGOF et du GEMVi [Menopause, menopause hormone therapy and osteoporosis. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines][J].Gynecol Obstet Fertil Senol,2021,49(5):420-437.DOI:10.1016/j.gofs.2021.03.015.
[8] Barrionuevo P,Kapoor E,Asi N,et al.Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis[J].J Clin Endocrinol Metab,2019,104(5):1623-1630.DOI:10.1210/jc.2019-00192.
[9] Kemmler W,Kohl M,Jakob F,et al.Effects of high intensity dynamic resistance exercise and whey protein supplements on osteosarcopenia in older men with low bone and muscle mass. Final results of the randomized controlled FrOST study[J].Nutrients,2020,12(8):2341.DOI:10.3390/nu12082341.
[10] 中华中医药学会.慢性肾衰竭诊疗指南[J].中国中医药现代远程教育,2011,9(9):132-133.DOI:10.3969/j.issn. 1672-2779.2011.09.090.
[11] 杜闯.高通量血液透析联合左卡尼汀治疗慢性肾衰竭患者的效果[J].中国民康医学,2022,34(15):43-46.DOI:10.3969/j.issn.1672-0369.2022.15.013.
[12] Li X,Guo H,Songjin S,et al.Speckle noise algorithm-based ultrasound imaging in evaluating the therapeutic effect of blood purification on children with kidney failure and analysis of its correlation with serum inflammatory factor levels[J].J Healthc Eng,2022,2022:3384102.DOI:10.1155/2022/3384102.
[13] Amutha J J .Effectiveness of selected nursing interventions on fatigue and quality of life among chronic renal failure patients undergoing hemodialysis in a selected hospital at madurai[J].International Journal of Advances in Nursing Management,2021:269-274.DOI:10.52711/2454-2652.2021.00061.
[14] 李欣.左卡尼汀治疗慢性肾衰竭透析患者心衰的临床效果分析[J].当代医学,2021,27(20):62-64.DOI:10.3969/j.issn.1009-4393.2021.20.026.
[15] Hamdan Almaeen A,Mostafa-Hedeab G.Haematological indicators of response to erythropoietin therapy in chronic renal failure patients on haemodialysis: impact of angiotensin-converting enzyme rs4343 gene polymorphism[J].Pharmgenomics Pers Med,2021,14:1055-1068.DOI:10.2147/PGPM.S311181.
[16] Stel VS,de Jong RW,Kramer A,et al.Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe[J].Kidney Int,2021,100(1):182-195.DOI:10.1016/j.kint.2020.12.010.
[17] Lan NSR,Nguyen LT,Vasikaran SD,et al.Short- and long-term biological variation of cardiac troponin I in healthy individuals, and patients with end-stage renal failure requiring haemodialysis or cardiomyopathy[J].Clin Chem Lab Med,2020,58(11):1941-1949.DOI:10.1515/cclm-2020-0046.
[18] Ariyani H,Robby A.Pruritus overview of chronic kidney failure patients using visual analogue scale application in hemodialysis unit general hospital dr. soekardjo, tasikmalaya city, west java[J].Journal of Physics:Conference Series,2020,1477(6):062014(5pp.DOI:10.1088/1742-6596/1477/6/062014.
[19] Maigoda T C ,Maisyorah E ,Krisnasary A ,et al.Energy, protein, and potassium intake with nutritional status among chronic renal failure patients undergoing hemodialysis in hospital Dr. M.Yunus, Bengkulu, Indonesia[J].Annals of Tropical Medicine and Public Health,2020,23(8):87.DOI:10.36295/ASRO.2020.23816.
[20] Song J ,Liu X ,Jiang W ,et al.Efficacy of goal-directed fluid therapy monitored by pulse-pressure variation using a continuous noninvasive arterial pressure monitoring system (the CNAPTM system) during parathyroidectomy in patients with end-stage renal failure – a randomised trial[J].Termedia Publishing House,2020,8(14):74.DOI:10.5114/AOMS.2020.95425
[21] Riyachan I,Subarnbhesaj A,Sarideechaigul W,et al.Oral manifestations of renal osteodystrophy in a patient with systemic lupus erythematosus with chronic renal failure and secondary hyperparathyroidism: a case report[J].J Dent Indones,2019,26(3):165-169.DOI:10.14693/jdi.v26i3.1003.
[22] Jah Yeon Choi,Chi Young Shim,Young-Guk Ko.Kidney diseases and conditions - acute kidney injury;Findings on acute kidney injury reported by researchers at university of health sciences[J].Computer Weekly News,2019,8(4):74.
[23] Geu-Ru Hong,Myeong-Ki Hong.Abstract 12713: Comparison of clinical outcome between noncontrast transcatheter aortic valve replacement with conventional transcatheter aortic valve replacement in patients with renal insufficiency[J].Circulation,2019,140(2):85.
[24] Lameire NH,Levin A,Kellum JA,et al.Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference[J].Kidney Int,2021,100(3):516-526.DOI:10.1016/j.kint.2021.06.028.
[25] Hsu CY,Chinchilli VM,Coca S,et al.Post-acute kidney injury proteinuria and subsequent kidney disease progression: the assessment, serial evaluation, and subsequent sequelae in acute kidney injury (ASSESS-AKI) study[J].JAMA Intern Med,2020,180(3):402-410.DOI:10.1001/jamainternmed.2019.6390.
[26] Kim H,Park JT,Lee J,et al.The difference between cystatin C- and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease[J].Atherosclerosis,2021,335:53-61.DOI:10.1016/j.atherosclerosis.2021.08.036.
[27] Chawla LS,Bellomo R,Bihorac A,et al.Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup[J].Nat Rev Nephrol,2017,13(4):241-257.DOI:10.1038/nrneph. 2017.2.
[28] Gulyaev NI,Akhmetshin IM,Gordienco AV,et al.[Sarcopenia as the reason of hypodiagnostics of chronic kidney disease in patients with chronic heart failure.][J].Adv Gerontol,2020,33(1):121-126.
[29] Davison SN,Levin A,Moss AH,et al.Executive summary of the KDIGO controversies conference on supportive care in chronic kidney disease: developing a roadmap to improving quality care[J].Kidney Int,2015,88(3):447-459.DOI:10.1038/ki.2015.110.
[30] Koc H,Hoser H,Akdag Y,et al.Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study[J].Int Urol Nephrol,2019,51(7):1261-1270.DOI:10.1007/s11255-019-02175-5.
[31] Kalantar-Zadeh K,Hollenbeak CS,Arguello R,et al.The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD[J].J Med Econ,2020,23(3):308-315.DOI:10.1080/13696998. 2019.1693385.
[32] 钟小桂.重组人促红素注射液与罗沙司他胶囊治疗维持性血液透析肾性贫血的效果及对血清Hb、SF、CRP的影响[J].吉林医学,2022,43(8):2153-2154.DOI:10.3969/j.issn. 1004-0412.2022.08.044.
[33] 赵娜,郭一丹,张春霞,等.重组人促红素联合左卡尼汀对老年血液透析患者肾性贫血治疗效果及氧化应激的影响[J].临床误诊误治,2021,34(4):33-38.DOI:10.3969/j.issn.1002-3429.2021.04.008.
[34] 刘华珍,郑黎明,董定国,等.肾康注射液联合重组人促红素对慢性肾衰竭透析患者血清血红蛋白、白蛋白水平的影响[J].中国药物经济学,2021,16(2):49-52.DOI:10.12010/j.issn.1673-5846.2021.02.011.
[35] 方蔷,张裕,姜东升,等.左卡尼汀联合重组人促红素对血液透析患者MDA、SOD、GSH-Px指标的影响[J].国际医药卫生导报,2020,26(20):3052-3055.DOI:10.3760/cma.j.issn.1007-1245.2020.20.014.